keyword
MENU ▼
Read by QxMD icon Read
search

souhami

keyword
https://www.readbyqxmd.com/read/28325618/thoracic-irradiation-in-3weeks-for-limited-stage-small-cell-lung-cancer-is-twice-a-day-fractionation-really-needed
#1
G A Turgeon, L Souhami, N Kopek, V Hirsh, L Ofiara, S L Faria
PURPOSE: Many Canadian institutions treat limited-disease small cell lung cancer with 40Gy in 15 fractions delivered once-a-day in 3weeks concomitantly with chemotherapy. This regimen is convenient and seems to be effective. Here, we report and compare with a literature review the outcomes of patients with limited-stage small cell lung cancer treated in our institution with this hypofractionated regimen. PATIENTS AND METHODS: From January 2004 to December 2012, patients with limited-stage small cell lung cancer treated curatively with platinum-based chemotherapy and concurrent thoracic radiotherapy at a dose of 40Gy in 16 fractions once-a-day were eligible for this review...
March 18, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28222995/acute-and-late-toxicity-in-high-risk-prostate-cancer-patients-treated-with-androgen-suppression-and-hypofractionated-pelvic-radiation-therapy
#2
Sergio Faria, Russel Ruo, Fabio Cury, Marie Duclos, Luis Souhami
PURPOSE: To report acute and late toxicity rates in patients with high-risk prostate cancer treated with androgen deprivation therapy (ADT) and moderate hypofractionated radiation therapy (HypoRT) to the prostate and nodal areas. METHODS AND MATERIALS: Patients with localized, high-risk prostate cancer were treated with a HypoRT regimen of 60 Gy in 20 fractions (4 weeks) to the prostate volume while the nodal areas received 44 Gy in the same 20 fractions delivered with intensity modulated RT with a simultaneous integrated boost technique...
January 20, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28146658/radiation-with-or-without-antiandrogen-therapy-in-recurrent-prostate-cancer
#3
RANDOMIZED CONTROLLED TRIAL
William U Shipley, Wendy Seiferheld, Himanshu R Lukka, Pierre P Major, Niall M Heney, David J Grignon, Oliver Sartor, Maltibehn P Patel, Jean-Paul Bahary, Anthony L Zietman, Thomas M Pisansky, Kenneth L Zeitzer, Colleen A F Lawton, Felix Y Feng, Richard D Lovett, Alexander G Balogh, Luis Souhami, Seth A Rosenthal, Kevin J Kerlin, James J Dignam, Stephanie L Pugh, Howard M Sandler
Background Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown. Methods In a double-blind, placebo-controlled trial conducted from 1998 through 2003, we assigned 760 eligible patients who had undergone prostatectomy with a lymphadenectomy and had disease, as assessed on pathological testing, with a tumor stage of T2 (confined to the prostate but with a positive surgical margin) or T3 (with histologic extension beyond the prostatic capsule), no nodal involvement, and a detectable PSA level of 0...
February 2, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28097324/molecular-based-recursive-partitioning-analysis-model-for-glioblastoma-in-the-temozolomide-era-a-correlative-analysis-based-on-nrg-oncology-rtog-0525
#4
Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, Mark R Gilbert, Minesh Mehta, Alexander C Klimowicz, Anthony Magliocco, Markus Bredel, Pierre Robe, Anca-L Grosu, Roger Stupp, Walter Curran, Aline P Becker, Andrea L Salavaggione, Jill S Barnholtz-Sloan, Kenneth Aldape, Deborah T Blumenthal, Paul D Brown, Jon Glass, Luis Souhami, R Jeffrey Lee, David Brachman, John Flickinger, Minhee Won, Arnab Chakravarti
Importance: There is a need for a more refined, molecularly based classification model for glioblastoma (GBM) in the temozolomide era. Objective: To refine the existing clinically based recursive partitioning analysis (RPA) model by incorporating molecular variables. Design, Setting, and Participants: NRG Oncology RTOG 0525 specimens (n = 452) were analyzed for protein biomarkers representing key pathways in GBM by a quantitative molecular microscopy-based approach with semiquantitative immunohistochemical validation...
January 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28032465/diurnal-glucose-exposure-profiles-of-patients-treated-with-lixisenatide-before-breakfast-or-the-main-meal-of-the-day-an-analysis-using-continuous-glucose-monitoring
#5
Richard M Bergenstal, Ellie Strock, Roger Mazze, Margaret A Powers, Arlene M Monk, Sara Richter, Elisabeth Souhami, Bo Ahren
BACKGROUND: In the parent study of this analysis, patients with type 2 diabetes received lixisenatide before breakfast or the main meal of the day. This sub-study was designed to examine the effect of lixisenatide administered before breakfast or the main meal of the day on continuously assessed 24-hour patient glucose profiles. METHODS: A subset of patients from the parent study underwent two 14-day periods of continuous glucose monitoring (CGM) at the start and end of the 24-week study...
December 29, 2016: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/28011051/a-phase-2-trial-of-neoadjuvant-temozolomide-followed-by-hypofractionated-accelerated-radiation-therapy-with-concurrent-and-adjuvant-temozolomide-for-patients-with-glioblastoma
#6
George Shenouda, Luis Souhami, Kevin Petrecca, Scott Owen, Valerie Panet-Raymond, Marie-Christine Guiot, Andrea Gomez Corredor, Bassam Abdulkarim
PURPOSE: We performed a phase 2 trial of neoadjuvant temozolomide (TMZ), followed by hypofractionated accelerated radiation therapy (HART) with concurrent TMZ, and adjuvant TMZ in patients with newly diagnosed glioblastoma to determine whether neoadjuvant TMZ would safely improve outcomes in this group of patients prior to subsequent cytotoxic therapy. METHODS AND MATERIALS: Adult patients with newly diagnosed glioblastoma and a Karnofsky Performance Status >60 were eligible...
March 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27780694/stereotactic-ablative-radiotherapy-versus-low-dose-rate-brachytherapy-or-external-beam-radiotherapy-propensity-score-matched-analyses-of-canadian-data
#7
A Loblaw, T Pickles, J Crook, A-G Martin, E Vigneault, L Souhami, F Cury, J Morris, C Catton, H Lukka, P Cheung, P Sethukavalan, A Warner, Y Yang, G Rodrigues
AIMS: To compare biochemical failure-free survival (BFFS) and overall survival for prostate cancer treated with stereotactic ablative radiotherapy (SABR), low dose rate (LDR) brachytherapy or external beam radiotherapy (EBRT) using a large Canadian multi-institutional database. MATERIALS AND METHODS: Patients with low risk localised prostate cancer treated with SABR, LDR or EBRT and no androgen deprivation therapy were selected. Propensity score matching was used to create two sets of matched cohorts with LDR and EBRT serving as control groups...
October 22, 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/27675942/updated-4-year-results-for-nrg-oncology-rtog-0921-a-phase-2-study-of-postoperative-intensity-modulated-radiation-therapy-with-concurrent-cisplatin-and-bevacizumab-followed-by-carboplatin-and-paclitaxel-for-patients-with-endometrial-cancer
#8
A N Viswanathan, K Winter, B E Miller, Y Xiao, A Jhingran, L Portelance, W R Bosch, U Matulonis, N Horowitz, R Mannel, L Souhami, B A Erickson, W Small, D K Gaffney
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27675736/second-malignancies-as-first-cause-of-death-in-localized-prostate-cancer-treated-with-radiation-therapy-data-from-two-phase-3-trials
#9
A Nabid, N Carrier, E Vigneault, L Souhami, C Lemaire, M A Brassard, B Bahoric, R Archambault, F Vincent, T V Nguyen
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27675716/funding-source-self-reported-conflicts-of-interest-and-the-interpretation-of-conclusions-of-phase-1-2-and-3-trials-in-neuro-oncology
#10
F Y Moraes, L C Mendez, J H Suh, N K Taunk, L Souhami, B J Slotman, E Weltman, G N Marta
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27675463/analysis-of-prognostic-factors-for-local-recurrence-in-atypical-meningiomas
#11
S I Shakir, L Souhami, K Petrecca, J J Mansure, S Khushdeep, V Panet-Raymond, G Shenouda, A Al Odaini, B S Abdulkarim, M C Guiot
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27674349/outcomes-of-adjuvant-therapy-in-stage-3-endometrial-cancer-confined-to-the-pelvis
#12
R M Albeesh, J Alfieri, J J Mansure, G A Turgeon, L Fu, J Arseneau, K Jardon, L Gilbert, L Souhami
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27673821/trial-sponsorship-and-self-reported-conflicts-of-interest-in-clinical-trials-of-central-nervous-system-malignancies
#13
L C Mendez, F Y Moraes, J H Suh, N K Taunk, L Souhami, B J Slotman, E Weltman, G N Marta
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27650977/efficacy-and-safety-of-lixilan-a-titratable-fixed-ratio-combination-of-insulin-glargine-plus-lixisenatide-in-type-2-diabetes-inadequately-controlled-on-basal-insulin-and-metformin-the-lixilan-l-randomized-trial
#14
Vanita R Aroda, Julio Rosenstock, Carol Wysham, Jeffrey Unger, Diego Bellido, Guillermo González-Gálvez, Akane Takami, Hailing Guo, Elisabeth Niemoeller, Elisabeth Souhami, Richard M Bergenstal
OBJECTIVE: This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) (100 units) and lixisenatide, compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to two oral glucose-lowering agents. RESEARCH DESIGN AND METHODS: After a 6-week run-in when iGlar was introduced and/or further titrated, and oral antidiabetic drugs other than metformin were stopped, 736 basal insulin-treated patients (mean diabetes duration 12 years, BMI 31 kg/m(2)) were randomized 1:1 to open-label, once-daily iGlarLixi or iGlar, both titrated to fasting plasma glucose <100 mg/dL (<5...
November 2016: Diabetes Care
https://www.readbyqxmd.com/read/27527848/benefits-of-lixilan-a-titratable-fixed-ratio-combination-of-insulin-glargine-plus-lixisenatide-versus-insulin-glargine-and-lixisenatide-monocomponents-in-type-2-diabetes-inadequately-controlled-on-oral-agents-the-lixilan-o-randomized-trial
#15
Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti, Pierre Serusclat, Xi Cheng, Tianyue Zhou, Elisabeth Niemoeller, Elisabeth Souhami, Melanie Davies
OBJECTIVE: To evaluate efficacy and safety of LixiLan (iGlarLixi), a novel titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both components, iGlar and Lixi, given separately in type 2 diabetes inadequately controlled on metformin with or without a second oral glucose-lowering drug. RESEARCH DESIGN AND METHODS: After a 4-week run-in to optimize metformin and stop other oral antidiabetic drugs, participants (N = 1,170, mean diabetes duration ∼8...
November 2016: Diabetes Care
https://www.readbyqxmd.com/read/27379211/big-data-analytics-for-prostate-radiotherapy
#16
REVIEW
James Coates, Luis Souhami, Issam El Naqa
Radiation therapy is a first-line treatment option for localized prostate cancer and radiation-induced normal tissue damage are often the main limiting factor for modern radiotherapy regimens. Conversely, under-dosing of target volumes in an attempt to spare adjacent healthy tissues limits the likelihood of achieving local, long-term control. Thus, the ability to generate personalized data-driven risk profiles for radiotherapy outcomes would provide valuable prognostic information to help guide both clinicians and patients alike...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27284114/efficacy-and-safety-of-lixilan-a-titratable-fixed-ratio-combination-of-lixisenatide-and-insulin-glargine-versus-insulin-glargine-in-type-2-diabetes-inadequately-controlled-on-metformin-monotherapy-the-lixilan-proof-of-concept-randomized-trial
#17
Julio Rosenstock, Michaela Diamant, Vanita R Aroda, Louise Silvestre, Elisabeth Souhami, Tianyue Zhou, Riccardo Perfetti, Vivian Fonseca
OBJECTIVE: This study assessed the efficacy and safety of LixiLan, a fixed-ratio, titratable, combination of 2 units insulin glargine (Gla-100) and 1 μg lixisenatide administered once daily via a single pen, versus Gla-100 in insulin-naïve type 2 diabetes on metformin. RESEARCH DESIGN AND METHODS: Participants were randomized to once-daily LixiLan (n = 161) or Gla-100 (n = 162) for 24 weeks, while continuing metformin. LixiLan and Gla-100 were started at 10 units/5 μg and 10 units, respectively, and titrated based on the Gla-100 requirement according to fasting plasma glucose levels...
September 2016: Diabetes Care
https://www.readbyqxmd.com/read/27222510/prandial-options-to-advance-basal-insulin-glargine-therapy-testing-lixisenatide-plus-basal-insulin-versus-insulin-glulisine-either-as-basal-plus-or-basal-bolus-in-type-2-diabetes-the-getgoal-duo-2-trial
#18
Julio Rosenstock, Bruno Guerci, Markolf Hanefeld, Sandro Gentile, Ronnie Aronson, Francisco J Tinahones, Christine Roy-Duval, Elisabeth Souhami, Marek Wardecki, Jenny Ye, Riccardo Perfetti, Simon Heller
OBJECTIVE: To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1-3 oral antidiabetic agents (OADs). RESEARCH DESIGN AND METHODS: Patients were randomized to lixisenatide once daily or insulin glulisine given once or thrice daily, added to glargine, with or without metformin, if HbA1c remained ≥7 to ≤9% (≥53 to ≤75 mmol/mol) after 12 weeks of glargine optimization with OADs other than metformin stopped at the start of optimization...
August 2016: Diabetes Care
https://www.readbyqxmd.com/read/27217852/enumerating-pelvic-recurrence-following-radical-cystectomy-for-bladder-cancer-a-canadian-multi-institutional-study
#19
Libni J Eapen, Edward Jones, Wassim Kassouf, Carole Lambert, Scott C Morgan, Madeleine Moussa, Robert Nam, Matthew Parliament, Laurie Russell, Fred Saad, D Robert Siemens, Luis Souhami, Ewa Szumacher, Scott Tyldesley, Yan Xu, Ingrid Zbieranowski, Rodney H Breau, Eric Belanger, Peter Black, Eric Estey, Julie Bowan, Bishwajit Bora, Michael Brundage, Peter Chung, Neil Fleshner, Andrew Evans, Glenn Bauman, Jonathan Izawa, Chris Davidson, Fadi Brimo
INTRODUCTION: We aimed to enumerate the rate of pelvic recurrence following radical cystectomy at university-affiliated hospitals in Canada. METHODS: Canadian, university-affiliated hospitals were invited to participate. They were asked to identify the first 10 consecutive patients undergoing radical cystectomy starting January 1, 2005, who had urothelial carcinoma stages pT3/T4 N0-2 M0. The first 10 consecutive cases starting January 1, 2005 who met these criteria were the patients submitted by that institution with information regarding tumour stage, age, number of nodes removed, and last known clinical status in regard to recurrence and patterns of failure...
March 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27085825/moderate-hypofractionated-external-beam-radiotherapy-alone-for-intermediate-risk-prostate-cancer-long-term-outcomes
#20
Sergio L Faria, Osmar B Neto, Fabio Cury, George Shenouda, Ruo Russel, Luis Souhami
INTRODUCTION: To report long term toxicity and efficacy of patients with intermediate risk prostate cancer treated with moderate hypofractionated radiotherapy (HypoRT). MATERIALS AND METHODS: We studied the first consecutive 100 men with intermediate risk (stage T2b-T2c, or PSA = 10-20 ug/L, or Gleason score = 7) adenocarcinoma of the prostate treated between October 2002 and May 2010 in our institution with moderate HypoRT. Patients were treated using three-dimensional conformal HypoRT to a dose of 66 Gy in 22 daily fractions prescribed to the isocenter...
April 2016: Canadian Journal of Urology
keyword
keyword
14147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"